Clearwater International has advised the shareholders of Sagitta Pharma on an LBO led by Isatis Capital, alongside the management team and BNP Paribas Développement
Clearwater International has advised BNP Paribas Développement, A Plus Finance and the founders of the Sagitta Pharma Group (Sagitta Pharma) on an LBO transaction led by Isatis Capital, alongside the management team and BNP Paribas Développement.
Founded in 2009 by two pharmacist brothers, Thomas and Jérôme Brunet, in the Tours region, the Group rapidly emerged as a disruptive player in the distribution of medicines and health products at the heart of the pharmacy ecosystem, notably through "La Centrale Pharma", France's first pharmaceutical central purchasing agency.
Supported since 2016 by A Plus Finance and BNP Paribas Développement, Sagitta Pharma developed a unique tool for independent pharmacies and pharmacy groups to cover the entire distribution of reimbursed and non-reimbursed medicines.
The range and depth of the Group's catalogue, as well as the flexibility of its offer, proved to be particularly relevant during the health crisis, enabling pharmacists to focus on their core business, patient advisory.
With sales over €55m, Sagitta Pharma has achieved solid double-digit annual growth over the past five years. The arrival of Isatis Capital alongside Jérôme Brunet, together with key managers and the reinvestment of BNP Paribas Développement, will enable the Group to accelerate its development both through organic growth, with the opening of new distribution areas, and through external growth, with several acquisition opportunities under consideration.